KRN5500: Additional Phase IIa data

Additional data from a double-blind, dose-escalation, U.S. Phase IIa trial in 19 patients with advanced cancer showed that a greater proportion of patients receiving 0.6-2.2 mg/m 2 KRN5500 achieved a ...